Who are CGB-500 Ointment with 1% tofacitinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-07293893, Leqselvi, Litfulo, Cibinqo, Vonjo, Cibinqo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cgb-500-ointment-with-1-tofacitinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CGB-500 Ointment with 1% tofacitinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CGB-500 Ointment with 1% tofacitinib (CGB-500 Ointment with 1% tofacitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

phase 2 JAK inhibitor JAK Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CGB-500 Ointment with 1% tofacitinib (CGB-500 Ointment with 1% tofacitinib) — CAGE Bio Inc.. Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CGB-500 Ointment with 1% tofacitinib TARGET	CGB-500 Ointment with 1% tofacitinib	CAGE Bio Inc.	phase 2	JAK inhibitor	JAK
Pf-07293893	pf-07293893	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Litfulo	Ritlecitinib Tosylate	Pfizer	marketed	Kinase inhibitor	Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family	2023-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Vonjo	PACRITINIB	Sobi	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	2022-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

Pfizer · 19 drugs in this class
Aclaris Therapeutics, Inc. · 2 drugs in this class
Beijing Friendship Hospital · 2 drugs in this class
Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
CAGE Bio Inc. · 1 drug in this class
CTI BioPharma · 1 drug in this class
Celgene · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class
LEO Pharma · 1 drug in this class
McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CGB-500 Ointment with 1% tofacitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/cgb-500-ointment-with-1-tofacitinib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab